Abstract
Clinical scenarios in progressive neurodegenerative diseases encompass a spectrum ranging from (ab)normal aging to dementia and movement disorders. Even during typical aging, there is a variable degree of accumulation of (micro)vascular pathology, amyloid deposition, and Lewy bodies. This reflects partly overlapping risk factors, e.g., for vascular disease and Alzheimer disease (AD). Instead of distinct diseases, there is oftentimes a coexistence of, for example, neurodegenerative AD type pathology and microvascular changes, which might even be supra-additive. Moreover, there is no strict relationship between the underlying pathology and the clinical presentation. For example, the accumulation of Lewy bodies might lead to Parkinson disease (movement disorder) or dementia with Lewy bodies (dementia), and imaging findings for those clinically different conditions may be overlapping and indistinguishable. Additionally, there is a substantial interindividual variability in resilience to disease manifestation or “cognitive reserve,” i.e., the same degree of neurodegeneration may lead to various degrees of clinical symptoms.
As a consequence, dementia syndromes and movement disorders in clinical neuroradiology may be considered as a partially overlapping spectrum of neurodegenerative diseases in terms of clinical presentation, underlying pathology, and imaging findings. Moreover, several types of pathology may potentially coexist. This is fundamentally different to most other domains of neuroradiology, in which patients have in general for example one specific histologic type of tumor, or one type of infection at a time. Consequently, the conclusion of radiology reports in neurodegenerative diseases is therefore often probabilistic rather than uniquely conclusive.
We provide suggestions for the most appropriate radiological techniques and image interpretation strategies for subjects suspected of a neurodegenerative or movement disorder including CT, MRI, PET imaging of glucose metabolism (FDG) and pathological deposits (amyloid and tau) and dopaminergic imaging, as well as an overview of the most important semiquantitative rating scales.
This publication is endorsed by: European Society of Neuroradiology (www.esnr.org)
References
Brown RK, Bohnen NI, Wong KK, Minoshima S, Frey KA. Brain PET in suspected dementia: patterns of altered FDG metabolism. Radiographics. 2014;34:684–701.
Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer’s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19:497–510.
Frisoni GB, Boccardi M, Barkhof F, et al. Strategic roadmap for an early diagnosis of Alzheimer’s disease based on biomarkers. Lancet Neurol. 2017;16:661–76.
Haller S, Vernooij MW, Kuijer JPA, Larsson EM, Jäger HR, Barkhof F. Cerebral microbleeds: imaging and clinical significance. Radiology. 2018;287:11–28.
Herrup K. The case for rejecting the amyloid cascade hypothesis. Nat Neurosci. 2015;18:794–9.
Jack CR, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer’s association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71:765–75.
Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10:698–712.
McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;89:88–100.
Muñoz-Ruiz MÁ, Hall A, Mattila J, et al. Using the disease state fingerprint tool for differential diagnosis of frontotemporal dementia and Alzheimer’s disease. Dement Geriatr Cogn Dis Extra. 2016;6:313–29.
Scheltens P, Blennow K, Breteler MM, et al. Alzheimer’s disease. Lancet. 2016.
Further Reading
Barkhof F, Haller S, Rombouts SA. Resting-state functional MR imaging: a new window to the brain. Radiology. 2014;272:29–49.
Biller A, Reuter M, Patenaude B, et al. Responses of the human brain to mild dehydration and rehydration explored in vivo by 1H-MR imaging and spectroscopy. AJNR Am J Neuroradiol. 2015;36:2277–84.
Chiotis K, Saint-Aubert L, Boccardi M, et al. Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:214–27.
Cordonnier C, Potter GM, Jackson CA, et al. Improving interrater agreement about brain microbleeds: development of the brain observer MicroBleed scale (BOMBS). Stroke. 2009;40:94–9.
Darcourt J, Booij J, Tatsch K, et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37:443–50.
de Souza LC, Chupin M, Bertoux M, et al. Is hippocampal volume a good marker to differentiate Alzheimer’s disease from frontotemporal dementia. J Alzheimers Dis. 2013;36:57–66.
Fällmar D, Haller S, Lilja J, et al. Arterial spin labeling-based Z-maps have high specificity and positive predictive value for neurodegenerative dementia compared to FDG-PET. Eur Radiol. 2017;27:4237–46.
Garibotto V, Herholz K, Boccardi M, et al. Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:183–95.
Gregoire SM, Chaudhary UJ, Brown MM, et al. The microbleed anatomical rating scale (MARS): reliability of a tool to map brain microbleeds. Neurology. 2009;73:1759–66.
Haller S, Barkhof F. Interaction of vascular damage and Alzheimer dementia: focal damage and disconnection. Radiology. 2017;282:311–3.
Haller S, Zaharchuk G, Thomas DL, Lovblad KO, Barkhof F, Golay X. Arterial spin labeling perfusion of the brain: emerging clinical applications. Radiology. 2016a;281:337–56.
Haller S, Falkovskiy P, Meuli R, et al. Basic MR sequence parameters systematically bias automated brain volume estimation. Neuroradiology. 2016b;58:1153–60.
Harper L, Barkhof F, Fox NC, Schott JM. Using visual rating to diagnose dementia: a critical evaluation of MRI atrophy scales. J Neurol Neurosurg Psychiatry. 2015;86:1225–33.
http://www.radiologyassistant.nl/en/p43dbf6d16f98d/dementia-role-of-mri.html
Jack CRJ, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9:119–28.
Jovicich J, Marizzoni M, Sala-Llonch R, et al. Brain morphometry reproducibility in multi-center 3T MRI studies: a comparison of cross-sectional and longitudinal segmentations. NeuroImage. 2013;83:472–84.
Mak HK, Qian W, Ng KS, et al. Combination of MRI hippocampal volumetry and arterial spin labeling MR perfusion at 3-tesla improves the efficacy in discriminating Alzheimer’s disease from cognitively normal elderly adults. J Alzheimers Dis. 2014;41:749–58.
Pereira JB, Cavallin L, Spulber G, et al. Influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cut-offs. J Intern Med. 2014;275:317–30.
Petersen RC. Alzheimer’s disease: progress in prediction. Lancet Neurol. 2010;9:4–5.
Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591–601.
Shams S, Fällmar D, Schwarz S, et al. MRI of the swallow tail sign: a useful marker in the diagnosis of Lewy body dementia. AJNR Am J Neuroradiol. 2017;38:1737–41.
Tomlinson BE, Blessed G, Roth M. Observations on the brains of non-demented old people. J Neurol Sci. 1968;7:331–56.
van de Pol LA, Hensel A, van der Flier WM, et al. Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2006;77:439–42.
Van Laere K, Varrone A, Booij J, et al. EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37:434–42.
Wattjes MP, Henneman WJ, van der Flier WM, et al. Diagnostic imaging of patients in a memory clinic: comparison of MR imaging and 64-detector row CT. Radiology. 2009;253:174–83.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this entry
Cite this entry
Haller, S., Garibotto, V., Barkhof, F. (2018). Neurodegenerative Disorders: Classification and Imaging Strategy. In: Barkhof, F., Jager, R., Thurnher, M., Rovira Cañellas, A. (eds) Clinical Neuroradiology. Springer, Cham. https://doi.org/10.1007/978-3-319-61423-6_78-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-61423-6_78-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-61423-6
Online ISBN: 978-3-319-61423-6
eBook Packages: Springer Reference MedicineReference Module Medicine